2014 - ERS Presidential Summit on breaking down barriers to lung health

ERS Presidential Summits are a forum for discussion in the interface between science and policy. The 2014 Presidential Summit hosted speakers from a range of fields, from policymakers to researchers and patients, coming together to discuss key issues in medicine development. More specifically the objectives of the 2014 Summit were to examine the various barriers to new medical products, from research to regulatory issues, and explore new ways to create a better environment for medicine development.

2014 - ERS Presidential Summit on breaking down barriers to lung health

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Introduction

P.J. Barnes (London, United Kingdom)

Slides

Accompanying documents

Better animal models of respiratory disease?

M. Belvisi (London, United Kingdom)

Accompanying documents

Alternatives to animal studies: virtual lung, human cells, in silico?

A. Holmes (London, United Kingdom)

Accompanying documents

Italian Presidency of the EU: health priorities

M. Marletta (Rome, Italy)

Accompanying documents

Revised EU directive clinical trials

F. Meunier (Brussels, Belgium)

Slides

Accompanying documents

National example: Italian Medicines' Agency

L. Pani (Rome, Italy)

Slides

Accompanying documents

Innovative Medicines Initiatives (IMI)

N. Seigneuret (Brussels, Belgium)

Slides

Accompanying documents

A national example: German Centre for Lung Research

W. Seeger (Giessen, Germany)

Slides

Accompanying documents

The Alliance for biomedical research in Europe

K. Sipido (Leuven, Belgium)

Accompanying documents

Regulatory aspects of respiratory drugs

S. Bonini (London, United Kingdom)

Slides

Accompanying documents

Benefit versus risk of innovation for industry

R. Strieter (Cambridge, United States of America)

Slides

Accompanying documents

Case study in cystic fibrosis: the US CF Foundation research and clinical development programmes

T. Ferkol (St. Louis, United States of America)

Slides

Accompanying documents

Patient's perspective I

K. Hansen (Denmark)

Slides

Accompanying documents

Patient's perspective II

F. Buccella (Rome, Italy)

Slides

Bench to bedside: what are the impediments to translational research

M. Rawlins (London, United Kingdom)

Slides

Accompanying documents

CDN Connection Issue

2014 - ERS Presidential Summit on breaking down barriers to lung health

2014 - ERS Presidential Summit on breaking down barriers to lung health

#{title}